Elevated LDL-C is directly associated with the development of ASCVD. Learn about current treatments, barriers in applying guideline-directed therapies, strategies for prioritizing LDL-C in clinical practice, combatting misinformation, and utilizing shared decision-making from guests Kim Prado, DNP, AGPCNP-BC, and Binu Koirala, PhD, MGS, RN, FAAN, FPCNA.

2018 Guideline for the Management of Blood Cholesterol: https://www.ahajournals.org/doi/10.1161/cir.0000000000000625 

2022 ACC Expert Consensus Decision Pathway on Role of Nonstatin Therapies for LDL-C Lowering in the Management of ASCVD Risk: https://www.jacc.org/doi/10.1016/j.jacc.2022.07.006

Evolving Management of LDL-C: https://www.ahajournals.org/doi/10.1161/JAHA.122.028892 

Shared Decision-Making and Cardiovascular Health: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001162 

JUPITER Trial: https://www.ahajournals.org/doi/full/10.1161/CIRCOUTCOMES.109.868299 

ASTEROID Trial: https://jamanetwork.com/journals/jama/fullarticle/202629 

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.